Position in CYTK
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$457,214
New position
Shares Held
5,367
first reported quarter
Ownership
0.004%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#313
of 477 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Gotham Asset Management, LLC holds $433,918,027 across 48 Biotechnology names. CYTK ranks #35 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
719,545 | $81,567,621 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
105,165 | $65,574,584 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
739,273 | $57,862,897 | |
| 4 | EXEL |
Exelixis, Inc.
|
892,663 | $48,569,793 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
1,349,465 | $47,757,566 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
112,014 | $26,992,013 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
120,702 | $22,605,070 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
42,051 | $12,658,612 |
All Filings in CYTK
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $457,214 | 5,367 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||